Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) and Lifecore Biomedical (NASDAQ:LFCR – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitability, dividends, institutional ownership and risk.
Profitability
This table compares Daiichi Sankyo and Lifecore Biomedical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Daiichi Sankyo | 10.92% | 14.35% | 6.10% |
| Lifecore Biomedical | -29.93% | N/A | -16.16% |
Risk and Volatility
Daiichi Sankyo has a beta of -0.11, meaning that its share price is 111% less volatile than the S&P 500. Comparatively, Lifecore Biomedical has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings for Daiichi Sankyo and Lifecore Biomedical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Daiichi Sankyo | 1 | 1 | 0 | 0 | 1.50 |
| Lifecore Biomedical | 1 | 4 | 0 | 0 | 1.80 |
Lifecore Biomedical has a consensus price target of $6.50, indicating a potential upside of 1.56%. Given Lifecore Biomedical’s stronger consensus rating and higher probable upside, analysts plainly believe Lifecore Biomedical is more favorable than Daiichi Sankyo.
Valuation & Earnings
This table compares Daiichi Sankyo and Lifecore Biomedical”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Daiichi Sankyo | $14.10 billion | 2.36 | $1.72 billion | $0.86 | 20.74 |
| Lifecore Biomedical | $128.87 million | 1.88 | -$40.50 million | ($1.07) | -5.98 |
Daiichi Sankyo has higher revenue and earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Daiichi Sankyo, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
83.4% of Lifecore Biomedical shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Daiichi Sankyo beats Lifecore Biomedical on 8 of the 13 factors compared between the two stocks.
About Daiichi Sankyo
Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.
About Lifecore Biomedical
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.
